{"id":"W4327675500","doi":"10.1038/s41467-023-37084-w","title":"Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Royal Victoria Regional Health Centre; Kingston Health Sciences Centre; Health Sciences Centre; McGill University Health Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; Princess Margaret Cancer Centre; London Health Sciences Centre; Royal Victoria Hospital; University of Toronto; University Health Network","funders":"Government of Ontario; Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation; American Society of Clinical Oncology; Conquer Cancer Foundation","keywords":"Medicine; PTEN; Oncology; Internal medicine; Clinical endpoint; Cohort; Clinical trial; Biomarker; Endometrial cancer; Cancer; PI3K/AKT/mTOR pathway; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004759833,0.0009706213,0.001569579,0.0002428669,0.0003053026,0.0008584801,0.0005251642,0.001058078,0.001743073],"category_scores_gemma":[0.002631934,0.0003539228,0.001274361,0.0003259444,0.0005259831,0.0005120238,0.0004149993,0.001786959,0.000384411],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006425657,"about_ca_system_score_gemma":0.001056123,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002450158,"about_ca_topic_score_gemma":0.0006085189,"domain_scores_codex":[0.9983259,0.001109758,0.0001072854,0.0002142291,0.0001459037,0.00009703587],"domain_scores_gemma":[0.9982172,0.0003775572,0.0005083935,0.000182642,0.0001591209,0.0005551827],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8579222,0.01961469,0.02148716,0.0009824297,0.002439511,0.000120641,0.0001552316,0.002500392,0.02792639,0.0001240737,0.001353331,0.06537403],"study_design_scores_gemma":[0.4065607,0.5086094,0.07033931,0.00009285571,0.002057575,0.0003916487,0.00007257303,0.002407909,0.006399337,0.0002542448,0.002731481,0.00008296254],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941302,0.00254851,0.000407678,0.000187919,0.00006634142,0.001271236,0.0005788082,0.00001916275,0.0007900697],"genre_scores_gemma":[0.9948461,0.0006200295,0.0007980146,0.0003702613,0.0000916689,0.00162637,0.00114739,0.000008387902,0.0004916831],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004759833,"threshold_uncertainty_score":0.02517271,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2313791015809039,"score_gpt":0.5199509745880829,"score_spread":0.288571873007179,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}